Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

1.

Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.

Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S.

Ophthalmology. 2008 Nov;115(11):1911-5. doi: 10.1016/j.ophtha.2008.05.007. Epub 2008 Jul 31.

PMID:
18672291
[PubMed - indexed for MEDLINE]
2.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
[PubMed - indexed for MEDLINE]
3.

Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

Melamud A, Stinnett S, Fekrat S.

Am J Ophthalmol. 2008 Jul;146(1):91-5. doi: 10.1016/j.ajo.2008.03.014. Epub 2008 May 2.

PMID:
18455144
[PubMed - indexed for MEDLINE]
4.

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators.

BMJ. 2010 Jun 9;340:c2459. doi: 10.1136/bmj.c2459.

PMID:
20538634
[PubMed - indexed for MEDLINE]
Free Article
5.

Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN.

Retina. 2007 Jun;27(5):535-40.

PMID:
17558313
[PubMed - indexed for MEDLINE]
6.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
[PubMed - indexed for MEDLINE]
7.

[Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].

Mackiewicz J, Mańkowska A, Dolar-Szczasny J, Zubilewicz A, Oleszczuk A, Nowomiejska K, Rejdak R, Zagórski Z.

Klin Oczna. 2007;109(4-6):146-9. Polish.

PMID:
17725273
[PubMed - indexed for MEDLINE]
8.

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.

Retina. 2006 May-Jun;26(5):495-511.

PMID:
16770255
[PubMed - indexed for MEDLINE]
9.

Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.

Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.

Ophthalmology. 2008 Feb;115(2):347-354.e2. Epub 2007 Jul 12.

PMID:
17628685
[PubMed - indexed for MEDLINE]
10.

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.

Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU.

Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78.

PMID:
17003454
[PubMed - indexed for MEDLINE]
Free Article
11.

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN.

Am J Ophthalmol. 2008 Feb;145(2):249-256. Epub 2007 Dec 11.

PMID:
18067876
[PubMed - indexed for MEDLINE]
12.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.

Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8.

PMID:
19590252
[PubMed - indexed for MEDLINE]
13.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
[PubMed - indexed for MEDLINE]
14.

Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.

Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.

Acta Ophthalmol. 2010 Aug;88(5):594-600. doi: 10.1111/j.1755-3768.2008.01485.x. Epub 2009 May 22.

PMID:
19485959
[PubMed - indexed for MEDLINE]
15.

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.

Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.

Retina. 2007 Apr-May;27(4):439-44.

PMID:
17420695
[PubMed - indexed for MEDLINE]
16.

Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.

Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, Ooto S, Sasahara M, Iwama D, Yoshimura N.

Retina. 2010 Mar;30(3):485-90. doi: 10.1097/IAE.0b013e3181bd2d51.

PMID:
19952993
[PubMed - indexed for MEDLINE]
17.

Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.

Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.

Ophthalmology. 2009 Apr;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057. Epub 2009 Feb 25.

PMID:
19243834
[PubMed - indexed for MEDLINE]
18.

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK.

Retina. 2007 Jun;27(5):541-51.

PMID:
17558314
[PubMed - indexed for MEDLINE]
19.

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D.

Clin Experiment Ophthalmol. 2008 Apr;36(3):252-6. doi: 10.1111/j.1442-9071.2008.01710.x.

PMID:
18412594
[PubMed - indexed for MEDLINE]
20.

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N.

Ophthalmology. 2005 Jun;112(6):1048-53.

PMID:
15885778
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk